01 / DESIGN
What was studied?
REDEFINE 2 randomized 1,206 adults with overweight or obesity and type 2 diabetes to cagrilintide-semaglutide or placebo, with lifestyle intervention, for 68 weeks.
02 / FINDINGS
What did the researchers report?
The combination group had greater average weight reduction and improved glycemic measures. Gastrointestinal adverse events were reported more often with the combination than with placebo.
03 / LIMITS
How should it be interpreted?
The trial compared the combination with placebo, not each component separately. It therefore cannot by itself isolate the contribution of each component, and its diabetes population should not be conflated with other trials.
Voltera Peptide editorial reading note. Based on the linked source record. Methods and corrections.